[The use of fraxiparin for the prevention and treatment of thromboembolism in patients with heparin-induced thrombocytopenia].
Seventeen patients aged 26-52 with recurrent thromboembolism of the veins and disturbances of cerebral and coronary circulation (3 and 2 cases, respectively) treated by unfractionated heparin developed thrombocytopenia in the presence of enhanced platelet aggregation. Despite heparin therapy, fresh thrombi of different sites appeared in 5 patients. A cross to fraxiparin (France) resulted in correction of thrombocytopenia, normalization of spontaneous platelet aggregation in two thirds of the patients. In 5 patients thrombocytopenia persisted. It is stated that in most cases low-molecular heparin allows continuation of antithrombotic therapy in heparin-induced thrombocytopenia. Neither transplacental passage nor hemostatic abnormalities in the newborns were recorded after administration of fraxiparin to 6 pregnant women.
Barkagan
Z S
ZS
D000328:Adult; D004211:Disseminated Intravascular Coagulation / Q000097:blood / Q000139:chemically induced / Q000150:complications; D004341:Drug Evaluation; D005260:Female; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017762:Nadroparin / Q000627:therapeutic use*; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000097:blood / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D012008:Recurrence; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced* / Q000150:complications; D013923:Thromboembolism / Q000097:blood / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control*
D017762:Nadroparin; D006493:Heparin
O primenenii fraksiparina dlia profilaktiki i lecheniia tromboémbolii u bol'nykh s indutsiruemoĭ geparinom trombotsitopenieĭ.